La Jolla Pharma preclinical data

LJPC said that in rats immunized with beta 2 GP1, a protein involved in blood clot formation, LJP 1082 treatment reduced antibodies against the antigen and B cells producing those antibodies by 90 percent. The company suggested that LJP 1082, which is in toxicology testing, may be useful to treat antiphospholipid syndrome, in which antibodies against beta 2 GP1 promote thrombosis. Data were presented at the Symposium on Antiphospholipid Antibodies in Tours. ...